Latest News

  • Early Infant Skin Microbiome Could Predict Eczema and Food Allergy

    Diagnostics World | A study published July in Allergy is one of the largest and most thorough longitudinal studies to date assessing how the infant skin microbiome changes in conjunction with atopic dermatitis (more commonly referred to as eczema), food sensitization, and food allergy.

    Oct 8, 2026

  • The Case for a ‘Payer-Lab Access Scorecard’

    Bio-IT World | Diagnostic labs have an underappreciated opportunity to team up with health plans on pilot programs focused on improving access to testing and reducing health disparities. The laboratory community should be thinking beyond medical policy coverage to design for completion, measure and address the gaps, and share accountability for action, advises Mark Hiatt, M.D., chief medical officer for the accreditation organization RadSite.

    Oct 6, 2026

  • Follow the Money: Vaginal Microbiome Testing, Gene Sequencing, Computational Microscopy

    Diagnostics World | Funding news from around the biotech space including investments in human tissue testing, oncology trial control data, AI protein design, more.

    Oct 1, 2026

  • WHO Lists Cepheid's Ebola Test, QIAGEN Receives FDA Clearance, ARPA-H Launches Autism Program

    Diagnostics World | Oracle and the Buck Institute collaborate on aging research; Mayo Clinic's Precure selects Helix as its multi-omics lab; Revvity launches an IVDR-certified type 1 diabetes screening test; and more.

    Sep 30, 2026

  • CareDx Expands AI Diagnostic Ecosystem for Transplant Patients

    Diagnostics World News | Since launching AlloSure Plus in July 2025, precision medicine company CareDx has been on a fast-moving expansion of AI-driven diagnostics aimed at one of medicine's highest-stakes patient populations: organ and bone marrow transplant recipients.

    Sep 29, 2026

  • Epigenetic Instability: Emerging Approach for Early Cancer Detection

    Diagnostics World News | Epigenetic instability, a measure of the chaotic nature of methylation in specific regions of circulating cell-free DNA (cfDNA), has emerged as a promising new approach for early cancer detection. In a recent proof-of-principle study, the metric outperformed conventional absolute methylation signatures in detecting early-stage breast and lung cancers.

    Sep 22, 2026